Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Sanofi SA — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.75, while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| JNK | SNY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $98.19 | $52.34 |
52-Week Low | $94.66 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $95.85, up 0.21% with a bearish technical signal from moving averages and oscillators neutral. Recent news highlights bond market volatility amid inflation data and Middle East tensions, with Fitch Ratings warning of AI-related corporate credit risks. The ETF maintains dividend distributions, with recent payouts around $0.52-$0.53.
Outlook is cautious due to macroeconomic headwinds and credit risks, but higher yields may attract income investors. Key risks include Fed policy uncertainty and oil price fluctuations impacting bond markets. Analyst sentiment is mixed, balancing yield appeal against fee concerns and market volatility.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
